Life-threatening disseminated enterovirus infection during combined rituximab and ibrutinib maintenance treatment for mantle cell lymphoma: a case report
Abstract Background Rituximab is a well-established component of treatment regimens for B-cell non-Hodgkin lymphoma. Rituximab binds the CD20 antigen on the surface of B lymphocytes, causing an enhanced clearance of malignant and benign B cells. Thus, rituximab leads to depletion of normal B lymphoc...
Main Authors: | Maximilian Higer, Denis Cana, Juergen Podlech, Simin Schadmand-Fischer, Andreas Schwarting, Daniel Teschner, Matthias Theobald, Thomas Wölfel, Georg Hess |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2020-08-01
|
Series: | Journal of Medical Case Reports |
Subjects: | |
Online Access: | http://link.springer.com/article/10.1186/s13256-020-02457-y |
Similar Items
-
Fatal Case of Enterovirus 71 Infection and Rituximab Therapy, France, 2012
by: Somar Kassab, et al.
Published: (2013-08-01) -
Favorable rituximab response in patients with refractory idiopathic inflammatory myopathies
by: Fernando Henrique Carlos de Souza, et al.
Published: (2018-09-01) -
Early addition of rituximab in the management of myositis associated with systemic lupus erythematosus
by: Mervat E Behiry, et al.
Published: (2019-01-01) -
Rituximab-induced neutropenia in a patient with inflammatory myopathy and systemic sclerosis overlap disease
by: Qasim Akram, et al.
Published: (2016-03-01) -
The use of rituximab in idiopathic inflammatory myopathies: description of a monocentric cohort and review of the literature
by: S. Barsotti, et al.
Published: (2018-07-01)